Dupixent® significantly reduced COPD exacerbations in the second positive Phase 3 trial.
The second Dupixent® (dupilumab) investigational Phase 3 chronic obstructive pulmonary disease (COPD) trial (NOTUS) has shown that Dupixent significantly reduced (34%) exacerbations, confirming positive published results from the landmark Phase 3 . The NOTUS trial also confirmed that treatment with…